T-win® is the first immune-modulating vaccine technology directed against both tumor cells and the most important immune-suppressive cells in the tumor microenvironment (TME).
Re-imagining cancer vaccines – the next frontier in immuno-oncology
First-in-class modulation of the tumor microenvironment (TME)
T-win® vaccines are designed to enable killing of both tumor cells and the most important immune-suppressive cells in the TME – Tregs and TAMs – to modulate the TME into an anti-tumor, pro-inflammatory environment. This novel and highly differentiated mechanism of action sets T-win® cancer vaccines apart from approved immune-oncology therapies that block a single immune-suppressing pathway or direct the immune system to target specific antigens.
Off-the-shelf cancer vaccine candidates designed to have broad utility
T-win® cancer vaccines are designed to target established and well-known immune-suppressive antigens that are widely expressed across tumor types, rather than rare or mutant antigens expressed only in a small number of patients’ tumors or tumor types. T-win® vaccines are intended to be used “off the shelf” – unlike neoantigen cancer vaccines, which must be personalized for each patient.
T-win® vaccines deliver peptide epitopes from immune-suppressive antigens, such as IDO, PD-L1 and arginase-1, to activate and expand T cells specific for those antigens.
These T cells induce potent anti-tumor immune responses within the TME in two ways:
- Direct killing of antigen-expressing tumor cells and immune-suppressive Tregs and TAMs
- Modulating the TME into a pro-inflammatory environment
The resulting immune-permissive TME allows more T cells to enter the TME for further tumor cell killing.